FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311473306> ?p ?o ?g. }

• W4311473306 endingPage "e2246915" @default.
• W4311473306 startingPage "e2246915" @default.
• W4311473306 abstract "Data describing the vaccine effectiveness (VE) and durability of BNT162b2 among children 5 to 11 years of age are needed.To estimate BNT162b2 VE against SARS-CoV-2 infection among children aged 5 to 11 years during Delta and Omicron variant-predominant periods and to further assess VE according to prior SARS-CoV-2 infection status and by sublineage during the Omicron variant-predominant period.This test-negative case-control study was conducted from November 2 to December 9, 2021 (Delta variant), and from January 16 to September 30, 2022 (Omicron variant), among 160 002 children tested at a large national US retail pharmacy chain, for SARS-CoV-2 via polymerase chain reaction (PCR); 62 719 children were tested during the Delta period, and 97 283 were tested during the Omicron period.Vaccination with BNT162b2 before SARS-CoV-2 testing vs no vaccination.The primary outcome was SARS-CoV-2 infection confirmed by PCR (regardless of the presence of symptoms), and the secondary outcome was confirmed symptomatic infection. Adjusted estimated VE was calculated from multilevel logistic regression models.A total of 39 117 children tested positive and 131 686 tested negative for SARS-CoV-2 (total, 170 803; 84 487 [49%] were boys; mean [SD] age was 9 [2] years; 74 236 [43%] were White non-Hispanic or non-Latino; and 37 318 [22%] were Hispanic or Latino). Final VE analyses included 160 002 children without SARS-CoV-2 infection less than 90 days prior. The VE of 2 doses of BNT162b2 against Delta was 85% (95% CI, 80%-89%; median follow-up, 1 month) compared with the Omicron period (20% [95% CI, 17%-23%]; median follow-up, 4 months). The adjusted VE of 2 doses against Omicron at less than 3 months was 39% (95% CI, 36%-42%), and at 3 months or more, it was -1% (95% CI, -6% to 3%). Protection against Omicron was higher among children with vs without infection 90 days or more prior but decreased in all children approximately 3 months after the second dose (58% [95% CI, 49%-66%] with infection vs 37% [95% CI, 34%-41%] without infection at <3 months; 27% [95% CI, 17%-35%] with infection vs -7% [95% CI, -12% to -1%] at ≥3 months without infection). The VE of 2 doses of BNT162b2 at less than 3 months by Omicron sublineage was 40% (95% CI, 36%-43%) for BA.1, 32% (95% CI, 21%-41%) for BA.2/BA.2.12.1, and 50% (95% CI, 37%-60%) for BA.4/BA.5. After 3 months or more, VE was nonsignificant for BA.2/BA.2.12.1 and BA.4/BA.5. The VE of a booster dose was 55% (95% CI, 50%-60%) against Omicron, with no evidence of waning at 3 months or more.This study suggests that, among children aged 5 to 11 years, 2 doses of BNT162b2 provided modest short-term protection against Omicron infection that was higher for those with prior infection; however, VE waned after approximately 3 months in all children. A booster dose restored protection against Omicron and was maintained for at least 3 months. These findings highlight the continued importance of booster vaccination regardless of history of prior COVID-19." @default.
• W4311473306 created "2022-12-26" @default.
• W4311473306 creator A5002262174 @default.
• W4311473306 creator A5009305511 @default.
• W4311473306 creator A5010458339 @default.
• W4311473306 creator A5032041479 @default.
• W4311473306 creator A5040702988 @default.
• W4311473306 creator A5058712635 @default.
• W4311473306 creator A5075087643 @default.
• W4311473306 creator A5077433815 @default.
• W4311473306 creator A5077928677 @default.
• W4311473306 creator A5089964898 @default.
• W4311473306 date "2022-12-14" @default.
• W4311473306 modified "2023-10-01" @default.
• W4311473306 title "Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age" @default.
• W4311473306 cites W3134815975 @default.
• W4311473306 cites W3187606327 @default.
• W4311473306 cites W3189960399 @default.
• W4311473306 cites W3214683919 @default.
• W4311473306 cites W4214628111 @default.
• W4311473306 cites W4214691085 @default.
• W4311473306 cites W4220692166 @default.
• W4311473306 cites W4280551210 @default.
• W4311473306 cites W4283717981 @default.
• W4311473306 cites W4283756122 @default.
• W4311473306 cites W4285281624 @default.
• W4311473306 cites W4285590921 @default.
• W4311473306 cites W4286009167 @default.
• W4311473306 doi "https://doi.org/10.1001/jamanetworkopen.2022.46915" @default.
• W4311473306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36515946" @default.
• W4311473306 hasPublicationYear "2022" @default.
• W4311473306 type Work @default.
• W4311473306 citedByCount "11" @default.
• W4311473306 countsByYear W43114733062023 @default.
• W4311473306 crossrefType "journal-article" @default.
• W4311473306 hasAuthorship W4311473306A5002262174 @default.
• W4311473306 hasAuthorship W4311473306A5009305511 @default.
• W4311473306 hasAuthorship W4311473306A5010458339 @default.
• W4311473306 hasAuthorship W4311473306A5032041479 @default.
• W4311473306 hasAuthorship W4311473306A5040702988 @default.
• W4311473306 hasAuthorship W4311473306A5058712635 @default.
• W4311473306 hasAuthorship W4311473306A5075087643 @default.
• W4311473306 hasAuthorship W4311473306A5077433815 @default.
• W4311473306 hasAuthorship W4311473306A5077928677 @default.
• W4311473306 hasAuthorship W4311473306A5089964898 @default.
• W4311473306 hasBestOaLocation W43114733061 @default.
• W4311473306 hasConcept C126322002 @default.
• W4311473306 hasConcept C144024400 @default.
• W4311473306 hasConcept C149923435 @default.
• W4311473306 hasConcept C151956035 @default.
• W4311473306 hasConcept C187212893 @default.
• W4311473306 hasConcept C203014093 @default.
• W4311473306 hasConcept C22070199 @default.
• W4311473306 hasConcept C2779134260 @default.
• W4311473306 hasConcept C3007834351 @default.
• W4311473306 hasConcept C3008058167 @default.
• W4311473306 hasConcept C524204448 @default.
• W4311473306 hasConcept C71924100 @default.
• W4311473306 hasConceptScore W4311473306C126322002 @default.
• W4311473306 hasConceptScore W4311473306C144024400 @default.
• W4311473306 hasConceptScore W4311473306C149923435 @default.
• W4311473306 hasConceptScore W4311473306C151956035 @default.
• W4311473306 hasConceptScore W4311473306C187212893 @default.
• W4311473306 hasConceptScore W4311473306C203014093 @default.
• W4311473306 hasConceptScore W4311473306C22070199 @default.
• W4311473306 hasConceptScore W4311473306C2779134260 @default.
• W4311473306 hasConceptScore W4311473306C3007834351 @default.
• W4311473306 hasConceptScore W4311473306C3008058167 @default.
• W4311473306 hasConceptScore W4311473306C524204448 @default.
• W4311473306 hasConceptScore W4311473306C71924100 @default.
• W4311473306 hasIssue "12" @default.
• W4311473306 hasLocation W43114733061 @default.
• W4311473306 hasLocation W43114733062 @default.
• W4311473306 hasLocation W43114733063 @default.
• W4311473306 hasOpenAccess W4311473306 @default.
• W4311473306 hasPrimaryLocation W43114733061 @default.
• W4311473306 hasRelatedWork W3113664224 @default.
• W4311473306 hasRelatedWork W3176864053 @default.
• W4311473306 hasRelatedWork W3198183218 @default.
• W4311473306 hasRelatedWork W4205317059 @default.
• W4311473306 hasRelatedWork W4205810683 @default.
• W4311473306 hasRelatedWork W4206548596 @default.
• W4311473306 hasRelatedWork W4206651655 @default.
• W4311473306 hasRelatedWork W4206669628 @default.
• W4311473306 hasRelatedWork W4224279380 @default.
• W4311473306 hasRelatedWork W3127156785 @default.
• W4311473306 hasVolume "5" @default.
• W4311473306 isParatext "false" @default.
• W4311473306 isRetracted "false" @default.
• W4311473306 workType "article" @default.